Reduced-dose CHOP therapy for elderly patients with non-Hodgkin's lymphoma

Citation
M. Mori et al., Reduced-dose CHOP therapy for elderly patients with non-Hodgkin's lymphoma, LEUK LYMPH, 41(3-4), 2001, pp. 359-366
Citations number
19
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Hematology,"Onconogenesis & Cancer Research
Journal title
LEUKEMIA & LYMPHOMA
ISSN journal
1042-8194 → ACNP
Volume
41
Issue
3-4
Year of publication
2001
Pages
359 - 366
Database
ISI
SICI code
1042-8194(200104)41:3-4<359:RCTFEP>2.0.ZU;2-7
Abstract
While CHOP therapy is effective for malignant lymphoma, the optimum schedul e for elderly patients remains controversial. The present study investigate d the usefulness of reduced-dose CHOP therapy for elderly patients. Previou sly untreated patients aged 65 years or older with intermediate to high-gra de non-Hodgkin's lymphoma were given up reduced-dose CHOP therapy at 3-week intervals. Group A patients were given 5/6 of the standard dose and Group B received 7/12 of the standard dose. Filgrastim was administered when the white blood cell count fell below 2,000 mu /L, Fifty-seven patients were ev aluable and the scheduled therapy was completed in 37. For patients aged fr om 65 to 79 years and for patients older than 80 years, the complete respon se rare was 79.5% and 46.2%, overall 3-year survival was 58.2% and 30.4%. a nd event-free 3-year survival was 49.3% and 44.4%. respectively. Major toxi cities (greater than or equal to grade 3) included leukopenia in 42 patient s and documented infection in 7 patients. Grade 3 cardiac plus renal failur e, grade 3 peritonitis due to small bowel perforation, and grade 3 liver dy sfunction occurred in 1 patient each. One patient died of toxicity (grade 4 hematological toxicity and pneumonia). In conclusion, it seems that in the elderly patients with non-Hodgkin's lym phoma, response to reduced-dose (5/6 dose) CHOP therapy is comparable to th at for standard CHOP in younger adults. mainly because of improved dose-int ensity.